-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★Pharmaceutical financingFonuogen received more than US$120 million in D2 round financing to accelerate the development of oncolytic virus therapy ★Lion Bio announced the FDA approval of its leading product LioCyx-M004 for the IND for the treatment of hepatocellular carcinoma Click on the picture for clinical application, register to participate in this conference.
There are several wonderful reports on the safety of delivery technology to share with you October 3, 2021/MedClub News/--The current conventional therapy for HIV is combined antiretroviral therapy Therapy (cART), although it can control the signs of infection, has a very high proportion of adverse reactions and is resistant to drugs
.
In order to find a more ideal and safe treatment in vivo, the research team at the Beckman Institute's Gene Therapy Center turned their attention to the exosome delivery system
.
On September 20, 2021, Nature Communications published a research paper entitled "Exosome-mediated stable epigenetic repression of HIV-1"
.
In the research, the team developed an HIV-1 promoter targeting Zinc Finger Protein (ZFP-362)
.
DNA methyltransferase 3a (DNMT3A) and other proteins in the cell epigenetic library can down-regulate HIV-1 transcription, and the promoter can be fused to the active region of DNA methyltransferase 3a to induce long-term HIV-1 Stable epigenetic suppression
.
In order to deliver the HIV-1 promoter, the researchers engineered the cells so that the secreted exosomes can produce RNA that encodes this HIV-1 inhibitory protein
.
▲ Exosome-mediated delivery of ZPAMt mRNA to virus-infected cells (Source: Literature) Researchers have used preclinical tests to prove the functionality of the delivery system and the targeted protein
.
In the human NSG mouse model, the inhibitory factor loaded with anti-HIV-1 exosomes can inhibit the expression of the virus.
This inhibitory mechanism is driven by the DNA methylation of HIV-1
.
This paved the way for an exosome-mediated delivery platform for therapeutic cargo systems, epigenetic suppression of HIV-1 infection
.
Exosomes: As a superior delivery system, exosomes have been used in many fields, such as tumors, strokes, and cardiovascular diseases
.
Some studies have demonstrated the direct therapeutic capabilities of exosomes, but more companies are currently focusing on the development of exosomes as a delivery system
.
Recommended reading: Artificially synthesized "programmable" exosomes show therapeutic potential and promote rapid wound healing.
Yimai Meng broke the news to find out the reason.
This is because of the natural characteristics of exosomes
.
First of all, as a natural way of communication between cells, exosomes are biocompatible and less toxic, so they are immunologically inert at the right time and can effectively reach the target without jeopardizing the normal health of nearby Cell
.
Furthermore, unlike other nanoparticle delivery systems, exosomes are easier to modify to target targets
.
In addition, there are many adhesion proteins on the surface of exosomes, which have become potential carriers in the field of gene therapy.
Nano-size and flexibility enable them to cross major biological barriers, such as the blood-brain barrier (BBB)
.
It can break through the blood-brain barrier
.
However, due to the different ways of communication between different cells, the composition of extracellular vesicles is complex, almost all processes in the human body require coordinated interactions between cells, the transmission between different cells, for how to regulate the transmission of information between cells Little is known about its specific mechanism, which limits the therapeutic application of exosomes to a certain extent
.
Recommended reading: Focus on the applications and challenges of exosomes! Is the spring of exosomes coming? Yimai New Observation Exosome Delivery Track On the exosome track, dozens of companies have deployed Codiak Bioscience, EVOX Therapeutics, Carmine Therapeutics, Capricor, Avalon, Aegle Therapeutics, etc.
internationally
.
The first two are the representative companies of the track
.
In May 2021, Reyon Pharmaceuticals and MDimune reached an agreement to jointly develop exosomal-delivered viral vaccines and mRNA treatments for rare genetic diseases
.
Recommended reading: Using exosome technology to deliver mRNA therapeutics in the bodyYimai Meng broke the news.
Codiak bioscience, a representative company among them, has been listed on NASDAQ in October 2020.
There are currently two pipelines entering the clinic: exoIL-12 and exoSTING
.
exoSTING is launching a Phase 1/2 clinical trial aimed at the treatment of solid tumors
.
ExoIL-12 is designed to treat solid tumors containing T cells and NK cells, and a phase 1 clinical trial of exoIL-12 has been initiated in healthy volunteers and patients with early-stage skin T-cell lymphoma
.
At present, its exoASO-STAT6 is the third most advanced product candidate, targeting bone marrow-related cancers
.
Evox Therapeutics is an exosome technology developer and DeliverEX platform is the company's proprietary exosome delivery platform
.
At present, the company's fastest-growing EVX-102 and EVX101 are still in the preclinical research stage
.
In the first half of 2020, Takeda and Eli Lilly each spent US$44 million on the exosome technology platform of Evox and reached cooperation terms based on their own needs
.
EVX-101 is exactly the project of EVOX and Takeda cooperation
.
Domestic companies deploying exosomes include Enzekangtai, Aisai Biological, Ensel Biological, and so on
.
The field of exosomes also includes many companies focusing on detection technology
.
Recommended reading: New Year's inventory: Which domestic companies have deployed exosomes Yimai Meng broke the news.
In July 2021, Enzekangtai announced the completion of a round A financing of nearly 100 million yuan, which is mainly used for the company's engineered exosome treatment pilot plant Construction, R&D of pre-clinical products, and construction of technology platform for exosomal engineering transformation
.
Recommended reading: Drug financingEnzekangtai completed nearly 100 million yuan of A round of financing to accelerate the research of exosomal drug delivery.
Reference materials: 1.
https://doi.
org/10.
1038/s41467-021-25839-2
There are several wonderful reports on the safety of delivery technology to share with you October 3, 2021/MedClub News/--The current conventional therapy for HIV is combined antiretroviral therapy Therapy (cART), although it can control the signs of infection, has a very high proportion of adverse reactions and is resistant to drugs
.
In order to find a more ideal and safe treatment in vivo, the research team at the Beckman Institute's Gene Therapy Center turned their attention to the exosome delivery system
.
On September 20, 2021, Nature Communications published a research paper entitled "Exosome-mediated stable epigenetic repression of HIV-1"
.
In the research, the team developed an HIV-1 promoter targeting Zinc Finger Protein (ZFP-362)
.
DNA methyltransferase 3a (DNMT3A) and other proteins in the cell epigenetic library can down-regulate HIV-1 transcription, and the promoter can be fused to the active region of DNA methyltransferase 3a to induce long-term HIV-1 Stable epigenetic suppression
.
In order to deliver the HIV-1 promoter, the researchers engineered the cells so that the secreted exosomes can produce RNA that encodes this HIV-1 inhibitory protein
.
▲ Exosome-mediated delivery of ZPAMt mRNA to virus-infected cells (Source: Literature) Researchers have used preclinical tests to prove the functionality of the delivery system and the targeted protein
.
In the human NSG mouse model, the inhibitory factor loaded with anti-HIV-1 exosomes can inhibit the expression of the virus.
This inhibitory mechanism is driven by the DNA methylation of HIV-1
.
This paved the way for an exosome-mediated delivery platform for therapeutic cargo systems, epigenetic suppression of HIV-1 infection
.
Exosomes: As a superior delivery system, exosomes have been used in many fields, such as tumors, strokes, and cardiovascular diseases
.
Some studies have demonstrated the direct therapeutic capabilities of exosomes, but more companies are currently focusing on the development of exosomes as a delivery system
.
Recommended reading: Artificially synthesized "programmable" exosomes show therapeutic potential and promote rapid wound healing.
Yimai Meng broke the news to find out the reason.
This is because of the natural characteristics of exosomes
.
First of all, as a natural way of communication between cells, exosomes are biocompatible and less toxic, so they are immunologically inert at the right time and can effectively reach the target without jeopardizing the normal health of nearby Cell
.
Furthermore, unlike other nanoparticle delivery systems, exosomes are easier to modify to target targets
.
In addition, there are many adhesion proteins on the surface of exosomes, which have become potential carriers in the field of gene therapy.
Nano-size and flexibility enable them to cross major biological barriers, such as the blood-brain barrier (BBB)
.
It can break through the blood-brain barrier
.
However, due to the different ways of communication between different cells, the composition of extracellular vesicles is complex, almost all processes in the human body require coordinated interactions between cells, the transmission between different cells, for how to regulate the transmission of information between cells Little is known about its specific mechanism, which limits the therapeutic application of exosomes to a certain extent
.
Recommended reading: Focus on the applications and challenges of exosomes! Is the spring of exosomes coming? Yimai New Observation Exosome Delivery Track On the exosome track, dozens of companies have deployed Codiak Bioscience, EVOX Therapeutics, Carmine Therapeutics, Capricor, Avalon, Aegle Therapeutics, etc.
internationally
.
The first two are the representative companies of the track
.
In May 2021, Reyon Pharmaceuticals and MDimune reached an agreement to jointly develop exosomal-delivered viral vaccines and mRNA treatments for rare genetic diseases
.
Recommended reading: Using exosome technology to deliver mRNA therapeutics in the bodyYimai Meng broke the news.
Codiak bioscience, a representative company among them, has been listed on NASDAQ in October 2020.
There are currently two pipelines entering the clinic: exoIL-12 and exoSTING
.
exoSTING is launching a Phase 1/2 clinical trial aimed at the treatment of solid tumors
.
ExoIL-12 is designed to treat solid tumors containing T cells and NK cells, and a phase 1 clinical trial of exoIL-12 has been initiated in healthy volunteers and patients with early-stage skin T-cell lymphoma
.
At present, its exoASO-STAT6 is the third most advanced product candidate, targeting bone marrow-related cancers
.
Evox Therapeutics is an exosome technology developer and DeliverEX platform is the company's proprietary exosome delivery platform
.
At present, the company's fastest-growing EVX-102 and EVX101 are still in the preclinical research stage
.
In the first half of 2020, Takeda and Eli Lilly each spent US$44 million on the exosome technology platform of Evox and reached cooperation terms based on their own needs
.
EVX-101 is exactly the project of EVOX and Takeda cooperation
.
Domestic companies deploying exosomes include Enzekangtai, Aisai Biological, Ensel Biological, and so on
.
The field of exosomes also includes many companies focusing on detection technology
.
Recommended reading: New Year's inventory: Which domestic companies have deployed exosomes Yimai Meng broke the news.
In July 2021, Enzekangtai announced the completion of a round A financing of nearly 100 million yuan, which is mainly used for the company's engineered exosome treatment pilot plant Construction, R&D of pre-clinical products, and construction of technology platform for exosomal engineering transformation
.
Recommended reading: Drug financingEnzekangtai completed nearly 100 million yuan of A round of financing to accelerate the research of exosomal drug delivery.
Reference materials: 1.
https://doi.
org/10.
1038/s41467-021-25839-2
